A Phase 1 interventional study of CHF6001 in Chronic Obstructive Pulmonary Disease (COPD) and COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tanimilast · Pulmonary Disease, Chronic Obstructive.
Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 1, and was the 9th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 30 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2021.
This study's enrollment of 8 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 46 across the 12 interventional studies. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A.: 5 open now, 5 under way, none of them phase 3. Of 62 finished, 7 (11%) have results posted.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 58th largest by enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2021, is one of 21 in phase 1, and was the 54th registered.
Chiesi Farmaceutici S.p.A.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 68 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.
This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.
The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14\^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.
Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of \[14\^C\]-labelled CHF6001
Drug: CHF6001
4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total
AUC(0-t_iv) for \[14\^C\] total in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total
C(max_iv) for \[14\^C\] total in plasma. C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total
t(max_iv) for \[14\^C\] total. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total
Area under curve extrapolated to infinity (AUC(0-∞_iv) for \[14\^C\] total in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total
Terminal half-life t(1/2_iv) for \[14\^C\] total and CHF6001. t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total
Blood to plasma ratio for \[14\^C\] total.
Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001
AUC(0-t_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001
C(max_iv) for \[14\^C\] CHF6001 in plasma. C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001
t(max_iv) for \[14\^C\] CHF6001. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001
Area under curve extrapolated to infinity (AUC0-∞_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001
Terminal half-life t(1/2_iv) for \[14\^C\] CHF6001 in plasma. t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001
Volume of distribution during the terminal phase (Vz_iv) of \[14\^C\] CHF6001 in plasma. Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001
Vdss_iv=Volume of distribution is calculated at steady-state for \[14\^C\] CHF6001 in plasma, after intravenous (iv) infusion administration.
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001
Systemic plasma clearance for \[14\^C\] CHF6001.
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001
Blood to plasma ratio for \[14\^C\] CHF6001.
Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001
AUC(0-t)_inh for CHF6001 in plasma. AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001
Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
PK Parameter -- C(max_inh) -- Plasma -- CHF6001
C(max_inh) for CHF6001 in plasma. C(max_inh)=Peak plasma concentration after inhalation of CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
PK Parameter -- t(max_inh) -- Plasma -- CHF6001
t(max_inh) for CHF6001 in plasma. t(max_inh)=Time to reach the Cmax after inhalation of CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001
AUC(0-∞_inh) for CHF6001 in plasma. AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001
Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001
t(1/2_inh) for CHF6001 in plasma. t(1/2_inh)=Terminal half-life, after inhalation of CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001
Absolute inhaled bioavailability for CHF6001. F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).
Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total
Urine excreted fraction for cumulative \[14\^C\] total.
Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001
Urine excreted fraction for cumulative \[14\^C\]-CHF6001. Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.
Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total
Fecal excreted fraction for cumulative \[14\^C\] total.
Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001
Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.
Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total
Urine and fecal excreted fraction for cumulative \[14\^C\] total.
Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001
Urine and Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.
Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
| Milestone | CHF6001 |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
AUC(0-t_iv) for \[14\^C\] total in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.
| h*ngEq/mL | CHF6001 |
|---|---|
| PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total | 5.4025 ± 16.7 |
C(max_iv) for \[14\^C\] total in plasma. C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration
| ngEq/mL | CHF6001 |
|---|---|
| PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total | 0.7072 ± 21.6 |
t(max_iv) for \[14\^C\] total. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
| h | CHF6001 |
|---|---|
| PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total | 0.217 (0.17 to 0.25) |
Area under curve extrapolated to infinity (AUC(0-∞_iv) for \[14\^C\] total in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
| h*ngEq/mL | CHF6001 |
|---|---|
| PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total | 6.0825 ± 19.6 |
Terminal half-life t(1/2_iv) for \[14\^C\] total and CHF6001. t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration
| h | CHF6001 |
|---|---|
| PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total | 72.4057 (56.446 to 105.776) |
Blood to plasma ratio for \[14\^C\] total.
| Ratio | CHF6001 |
|---|---|
| PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total | 0.6490 ± 23.9 |
AUC(0-t_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration
| h*ng/mL | CHF6001 |
|---|---|
| PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001 | 0.7825 ± 18.2 |
C(max_iv) for \[14\^C\] CHF6001 in plasma. C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration
| ng/mL | CHF6001 |
|---|---|
| PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001 | 0.6312 ± 19.1 |
t(max_iv) for \[14\^C\] CHF6001. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
| h | CHF6001 |
|---|---|
| PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001 | 0.217 (0.17 to 0.25) |
Area under curve extrapolated to infinity (AUC0-∞_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
| h*ng/mL | CHF6001 |
|---|---|
| PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001 | 0.8138 ± 18.6 |
Terminal half-life t(1/2_iv) for \[14\^C\] CHF6001 in plasma. t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration
| h | CHF6001 |
|---|---|
| PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001 | 13.5816 (6.452 to 33.092) |
Volume of distribution during the terminal phase (Vz_iv) of \[14\^C\] CHF6001 in plasma. Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration
| Litres | CHF6001 |
|---|---|
| PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001 | 436.1078 ± 38.6 |
Vdss_iv=Volume of distribution is calculated at steady-state for \[14\^C\] CHF6001 in plasma, after intravenous (iv) infusion administration.
| Litres | CHF6001 |
|---|---|
| PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001 | 201.2514 ± 36.2 |
Systemic plasma clearance for \[14\^C\] CHF6001.
| Litres/h | CHF6001 |
|---|---|
| PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001 | 21.9951 ± 18.6 |
Blood to plasma ratio for \[14\^C\] CHF6001.
| Ratio | CHF6001 |
|---|---|
| PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001 | 0.5166 ± 54.9 |
AUC(0-t)_inh for CHF6001 in plasma. AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001
| h*pg/mL | CHF6001 |
|---|---|
| PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001 | 71088 ± 28.2 |
C(max_inh) for CHF6001 in plasma. C(max_inh)=Peak plasma concentration after inhalation of CHF6001
| pg/mL | CHF6001 |
|---|---|
| PK Parameter -- C(max_inh) -- Plasma -- CHF6001 | 1979 ± 22.5 |
t(max_inh) for CHF6001 in plasma. t(max_inh)=Time to reach the Cmax after inhalation of CHF6001
| h | CHF6001 |
|---|---|
| PK Parameter -- t(max_inh) -- Plasma -- CHF6001 | 2.008 (2.00 to 3.75) |
AUC(0-∞_inh) for CHF6001 in plasma. AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001
| h*pg/mL | CHF6001 |
|---|---|
| PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001 | 72403 ± 28.4 |
t(1/2_inh) for CHF6001 in plasma. t(1/2_inh)=Terminal half-life, after inhalation of CHF6001
| h | CHF6001 |
|---|---|
| PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001 | 41.5691 (25.930 to 45.159) |
Absolute inhaled bioavailability for CHF6001. F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).
| Ratio | CHF6001 |
|---|---|
| PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001 | 0.4977 ± 26.8 |
Urine excreted fraction for cumulative \[14\^C\] total.
| Cumulative % of dose excreted in urine | CHF6001 |
|---|---|
| 0-4 h | 1.99 ± 0.523 |
| 4-8 h | 3.26 ± 0.552 |
| 8-12 h | 3.93 ± 0.549 |
| 12-24 h | 5.24 ± 0.554 |
| 24-48 h | 6.77 ± 0.519 |
| 48-72 h | 7.35 ± 0.553 |
| 72-96 h | 7.64 ± 0.622 |
| 96-120 h | 7.80 ± 0.673 |
| 120-144 h | 7.89 ± 0.703 |
| 144-168 h | 7.96 ± 0.720 |
| 168-192 h | 8.01 ± 0.729 |
| 192-216 h | 8.06 ± 0.763 |
| 216-240 h | 8.10 ± 0.771 |
Urine excreted fraction for cumulative \[14\^C\]-CHF6001. Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.
| (%) percent of injected [14C]-CHF6001 | CHF6001 |
|---|---|
| 0-4 h | 0.00 ± 0.00 |
| 0-8 h | 0.00 ± 0.00 |
| 0-12 h | 0.00 ± 0.00 |
| 0-24 h | 0.00 ± 0.00 |
| 0-48 h | 0.00 ± 0.00 |
| 0-72 h | 0.00 ± 0.00 |
| 0-96 h | 0.00 ± 0.00 |
| 0-120 h | 0.00 ± 0.00 |
| 0-144 h | 0.00 ± 0.00 |
| 0-168 h | 0.00 ± 0.00 |
| 0-192 h | 0.00 ± 0.00 |
| 0-216 h | 0.00 ± 0.00 |
| 0-240 h | 0.00 ± 0.00 |
Fecal excreted fraction for cumulative \[14\^C\] total.
| Cumulative % of dose excreted in feces | CHF6001 |
|---|---|
| 0-24 h | 7.64 ± 12.0 |
| 24-48 h | 38.9 ± 20.6 |
| 48-72 h | 57.7 ± 8.53 |
| 72-96 h | 64.9 ± 4.26 |
| 96-120 h | 68.6 ± 2.35 |
| 120-144 h | 69.6 ± 2.08 |
| 144-168 h | 70.0 ± 2.09 |
| 168-192 h | 70.5 ± 2.19 |
| 192-216 h | 70.7 ± 2.22 |
| 216-240 h | 70.8 ± 2.26 |
Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.
| (%) percent of injected [14C]-CHF6001 | CHF6001 |
|---|---|
| 0-24 h | 0.0435 ± 0.0676 |
| 0-48 h | 0.1748 ± 0.0895 |
| 0-72 h | 0.2507 ± 0.0855 |
| 0-96 h | 0.2816 ± 0.0685 |
| 0-120 h | 0.3048 ± 0.0660 |
| 0-144 h | 0.3060 ± 0.0642 |
| 0-168 h | 0.3060 ± 0.0642 |
| 0-192 h | 0.3060 ± 0.0642 |
| 0-216 h | 0.3060 ± 0.0642 |
| 0-240 h | 0.3060 ± 0.0642 |
Urine and fecal excreted fraction for cumulative \[14\^C\] total.
| Cumulative % of dose excreted | CHF6001 |
|---|---|
| 0-4 h | 1.99 ± 0.523 |
| 4-8 h | 3.26 ± 0.552 |
| 8-12 h | 3.93 ± 0.549 |
| 12-24 h | 12.9 ± 12.3 |
| 24-48 h | 45.6 ± 20.8 |
| 48-72 h | 65.1 ± 8.67 |
| 72-96 h | 72.5 ± 4.12 |
| 96-120 h | 76.4 ± 2.46 |
| 120-144 h | 77.5 ± 2.23 |
| 144-168 h | 77.9 ± 2.32 |
| 168-192 h | 78.5 ± 2.46 |
| 192-216 h | 78.7 ± 2.51 |
| 216-240 h | 78.9 ± 2.58 |
Urine and Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.
| (%) percent of injected [14C]-CHF6001 | CHF6001 |
|---|---|
| 0-24 h | 0.0435 ± 0.0676 |
| 0-48 h | 0.1748 ± 0.0895 |
| 0-72 h | 0.2507 ± 0.0855 |
| 0-96 h | 0.2816 ± 0.0685 |
| 0-120 h | 0.3048 ± 0.0660 |
| 0-144 h | 0.3060 ± 0.0642 |
| 0-168 h | 0.3060 ± 0.0642 |
| 0-192 h | 0.3060 ± 0.0642 |
| 0-216 h | 0.3060 ± 0.0642 |
| 0-240 h | 0.3060 ± 0.0642 |
Collected over Adverse events were monitored from the time of the Informed Consent signature (screening visit at 31 to 3 days before the study treatment administration) until the subject's study participation ended (follow-up phone call or visit at 7 to 10 days after discharge or premature discontinuation).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF6001 | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | CHF6001 |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/8 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/8 |
| Abdominal pain lowerGastrointestinal disorders | 1/8 |
Healthy male subjects.
| Age, Continuous(years) | CHF6001 |
|---|---|
| Mean | 36.3 ± 4.4 |
| Sex: Female, Male(Participants) | CHF6001 |
|---|---|
| Female | 0 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | CHF6001 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | CHF6001 |
|---|---|
| United Kingdom | 8 |
| Body mass index(kg/m^2) | CHF6001 |
|---|---|
| Mean | 28.09 ± 4.73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Apr 2021, 1 month.
Results were first posted in Mar 2024, 2 years 10 months after primary completion.
Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 1 month is below that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tanimilast
Pulmonary Disease, Chronic Obstructive →